As of 2025-09-18, the EV/EBITDA ratio of Spero Therapeutics Inc (SPRO) is -1.35. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SPRO's latest enterprise value is 75.74 mil USD. SPRO's TTM EBITDA according to its financial statements is -56.28 mil USD. Dividing these 2 quantities gives us the above SPRO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.4x - 13.6x | 11.0x |
| Forward P/E multiples | 12.3x - 19.2x | 15.8x |
| Fair Price | (11.75) - (13.05) | (12.82) |
| Upside | -718.2% - -786.6% | -774.8% |
| Date | EV/EBITDA |
| 2025-09-16 | -1.35 |
| 2025-09-15 | -1.33 |
| 2025-09-12 | -1.35 |
| 2025-09-11 | -1.40 |
| 2025-09-10 | -1.39 |
| 2025-09-09 | -1.43 |
| 2025-09-08 | -1.44 |
| 2025-09-05 | -1.60 |
| 2025-09-04 | -1.59 |
| 2025-09-03 | -1.53 |
| 2025-09-02 | -1.50 |
| 2025-08-29 | -1.52 |
| 2025-08-28 | -1.45 |
| 2025-08-27 | -1.43 |
| 2025-08-26 | -1.30 |
| 2025-08-25 | -1.30 |
| 2025-08-22 | -1.32 |
| 2025-08-21 | -1.31 |
| 2025-08-20 | -1.28 |
| 2025-08-19 | -1.29 |
| 2025-08-18 | -1.36 |
| 2025-08-15 | -1.36 |
| 2025-08-14 | -1.43 |
| 2025-08-13 | -1.38 |
| 2025-08-12 | -1.81 |
| 2025-08-11 | -1.65 |
| 2025-08-08 | -1.64 |
| 2025-08-07 | -1.62 |
| 2025-08-06 | -1.71 |
| 2025-08-05 | -1.57 |
| 2025-08-04 | -1.71 |
| 2025-08-01 | -1.75 |
| 2025-07-31 | -1.77 |
| 2025-07-30 | -1.62 |
| 2025-07-29 | -1.65 |
| 2025-07-28 | -1.75 |
| 2025-07-25 | -1.78 |
| 2025-07-24 | -1.80 |
| 2025-07-23 | -1.83 |
| 2025-07-22 | -1.86 |
| 2025-07-21 | -1.77 |
| 2025-07-18 | -1.82 |
| 2025-07-17 | -1.93 |
| 2025-07-16 | -1.92 |
| 2025-07-15 | -1.94 |
| 2025-07-14 | -2.09 |
| 2025-07-11 | -2.26 |
| 2025-07-10 | -2.29 |
| 2025-07-09 | -2.49 |
| 2025-07-08 | -2.39 |